Drugs / IBI325
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05246995 | Mar 2022 → Mar 2023 | neoplasm | Shandong Cancer Hospital and Institute | Unknown | No outcome recorded |
| Phase 1 | NCT05119998 | Feb 2022 → Jul 2023 | cancer | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IBI325 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05246995 ↗ |